Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06455826 · ClinicalTrials.gov registry record · Phase 1
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
A Phase 1 study of Eye Diseases and Retinal Disease, sponsored by PYC Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 5
- Study locations
NCT06455826: Recruiting Phase 1 study of Eye Diseases and Retinal Disease, sponsored by PYC Therapeutics.
NCT06455826 is a Phase 1 study of Eye Diseases and Retinal Disease that is actively recruiting participants, run by PYC Therapeutics. The registered enrollment target is 12 participants, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06455826, a Phase 1 study of Eye Diseases and Retinal Disease, is actively recruiting participants, sponsored by PYC Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Conditions Studied
Interventions
- DRUG VP-001
Study Locations (5)
Texas
- Retina Foundation of the Southwest - Dallas
- Baylor College of Medicine- Alkek Eye Center - Houston
Florida
- University of Florida Health - Jacksonville
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Oregon
- Oregon Health and Science University - Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
What NCT06455826 shows while recruiting
NCT06455826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 5 conditions, with Eye Diseases appearing as the primary indexed condition, and to 1 intervention - of which VP-001 is the first listed.
NCT06455826 lists 5 locations in 4 states (Texas, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT06455826 about?
NCT06455826 is a clinical study titled "MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)". A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
What is the current status of trial NCT06455826?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-06-13. Estimated completion is 2025-11.
What conditions does trial NCT06455826 study?
This clinical trial studies the following conditions: Eye Diseases, Retinal Disease, Retinal Degeneration, Retinal Dystrophies, Retinitis Pigmentosa 11.
What interventions are being tested in trial NCT06455826?
The interventions under investigation include: VP-001 (DRUG).
Who is sponsoring clinical trial NCT06455826?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06455826 being conducted?
This trial has 5 study locations across Florida, Michigan, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06455826's enrollment target sits among peer trials
12 27th of 27 higher than 1 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ACTIVE NOT RECRUITING · Phase 1
-
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
COMPLETED · Phase 1
-
Adaptive Optics Retinal Imaging
RECRUITING
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI